Abstract: A compound of the structure ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen or --CONH(CR.sup.3 R.sup.4).sub.n --X;R.sup.3 and R.sup.4 are each, independently, hydrogen, alkyl, aralkyl, cycloalkyl, halogen, or trifluoromethyl;X ix hydrogen, lower alkyl, cycloalkyl, trifluoromethyl, nitro, alkoxy, carboalkoxy, aralkyl, halo, dialkylamino, thioalkyl, or Y;Y is a phenyl group which may be optionally mono-, di-, or tri- substituted with a group selected from alkyl, aralkyl, alkoxy, cyano, halo, nitro, carbalkoxy, trifluoromethyl, dialkylamino, or alkylthio;n=0-5;with the proviso that R.sup.1 and R.sup.2 are not both hydrogen and when n=0, X is lower alkyl, cycloalkyl, aralkyl, or Y;or a pharmaceutically acceptable salt thereof when X is dialkylamino, which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs.

Abstract: Derivatives of 11-deoxy-PGE.sub.2 are prepared. These new compounds not heretofore found in nature possess various pharmacological activities, one of which is bronchodilation.

Abstract: Prostaglandin compounds substituted at the 11-position, and possessing bronchodilating and hypotensive activity are prepared from PGA.sub.2 and its esters and 15-epimers.

Abstract: The preparation of the methyl esters of 16-keto prostaglandin E.sub.2 and 15-epi-16-keto prostaglandin E.sub.2 is described. The compounds have hypotensive activity.

Abstract: Derivatives of PGD.sub.2 are prepared. These new compounds not heretofore found in nature display pharmacological activity, for example, inhibition of blood platelet aggregation.

Abstract: Processes for the total synthesis of dl-11-deoxy-15-substituted prostaglandins, novel intermediates therefore, certain novel final products, as well as optical resolutions of the final products are disclosed.The final products are bronchodilators.

Abstract: Prostaglandin compounds substituted at the 11-position with a methyl group are prepared from PGA.sub.2, its 15-epimer, and their esters. These compounds, not heretofore found in nature, possess a variety of pharmacological activities one of which is bronchodilation.

Abstract: Processes for the total synthesis of dl-11-deoxy-15-substituted prostaglandins, novel intermediates therefore, certain novel final products, as well as optical resolutions of the final products are disclosed.The final products are bronchodilators.

Abstract: The topical application of 7-(5.alpha.-hydroxy-2.beta.-[(3RS)-3-hydroxy-3-methyl-trans-1-octenyl]-3.a lpha.-methyl-1.alpha.-cyclopentyl)-cis-5-heptenoic acid, 7-(5.alpha.-hydroxy-2.beta.-[(3RS)-3-hydroxy-3-methyl-trans-1-octenyl]-1.a lpha.-cyclopentyl)-cis-5-heptenoic acid, or 7-(2.beta.-[(3RS)-hydroxy-3-methyl-trans-1-octenyl]-5-oxo-1.alpha.-cyclope ntyl)-cis-5-heptenoic acid to a wound surface can be employed to attenuate bleeding. The compounds are prepared from the prostaglandin PGA.sub.2.

Abstract: 11.alpha.-Cyano-15-substituted PGE.sub.1 analogs, related compounds and intermediates thereto are disclosed. The final products have bronchodilatory, or anti-inflammatory activity.

Abstract: The topical application of 7-(5.alpha.-hydroxy-2.beta.-[(3RS)-3-hydroxy-3-methyl-trans-1-octenyl]-3.a lpha.-methyl-1.alpha.-cyclopentyl)-cis-5-heptenoic acid, 7-(5.alpha.-hydroxy-2.beta.-[(3RS)-3-hydroxy-3-methyl-trans-1-octenyl]-1.a lpha.-cyclopentyl)-cis-5-heptenoic acid, or 7-(2.beta.-[(3RS)-hydroxy-3-methyl-trans-1-octenyl]-5-oxo-1.alpha.-cyclope ntyl)-cis-5-heptenoic acid to a wound surface can be employed to attenuate bleeding. The compounds are prepared from the prostaglandin PGA.sub.2.